Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway
Cheng Chen, Chuan-dong Cheng, Hong Wu, Zuowei Wang, Li Wang, Zongru Jiang, Aoli Wang, Chen Hu, Yongfei Dong, Wanxiang Niu, Shuang Qi, Ziping Qi, Jing Liu, Wenchao Wang, Chaoshi Niu, Qingsong Liu
Topics & Concepts
OsimertinibMAPK/ERK pathwayCancer researchKinasePhosphorylationMedicineEpidermal growth factor receptorPharmacologyChemistryBiologyCancerInternal medicineCell biologyErlotinibPI3K/AKT/mTOR signaling in cancerMelanoma and MAPK PathwaysQuinazolinone synthesis and applications